Scarica l'app Stockscreener
29.73
0.87%
-0.26
Precedente Chiudi:
$29.99
Aprire:
$29.78
Volume 24 ore:
242.43K
Relative Volume:
0.70
Capitalizzazione di mercato:
$492.64M
Reddito:
$99.61M
Utile/perdita netta:
$-153.60M
Rapporto P/E:
-1.8075
EPS:
-16.4479
Flusso di cassa netto:
$-152.14M
1 W Prestazione:
-2.30%
1M Prestazione:
+13.95%
6M Prestazione:
+143.09%
1 anno Prestazione:
+263.54%
Intervallo 1D:
$27.80
$30.13
Intervallo di 1 settimana:
$27.80
$33.35
Portata 52W:
$7.15
$43.85
Sutro Biopharma Inc Stock (STRO) Company Profile
Nome
Sutro Biopharma Inc
Settore
Industria
Telefono
650-392-8412
Indirizzo
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare STRO vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
STRO
Sutro Biopharma Inc
|
29.73 | 492.64M | 99.61M | -153.60M | -152.14M | -16.45 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-07 | Iniziato | Leerink Partners | Outperform |
| 2026-03-24 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2026-03-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-01-20 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-06-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-03-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-03-14 | Downgrade | BofA Securities | Buy → Underperform |
| 2025-03-14 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-05-08 | Iniziato | BofA Securities | Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Buy |
| 2023-10-06 | Iniziato | Oppenheimer | Outperform |
| 2023-03-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-08-18 | Ripresa | Wells Fargo | Overweight |
| 2021-06-18 | Iniziato | H.C. Wainwright | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-09-02 | Iniziato | Jefferies | Buy |
| 2020-07-16 | Iniziato | Wells Fargo | Overweight |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-10-07 | Iniziato | BTIG Research | Buy |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2019-04-29 | Iniziato | H.C. Wainwright | Buy |
| 2018-10-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2018-10-22 | Iniziato | Piper Jaffray | Overweight |
| 2018-10-22 | Iniziato | Wedbush | Outperform |
Mostra tutto
Sutro Biopharma Inc Borsa (STRO) Ultime notizie
Sutro Biopharma (STRO) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Sutro Biopharma (STRO) 2024 Wells Fargo Healthcare Conference Summary - Quartr
Enterprise value to EBITDA forward of Sutro Biopharma, Inc. – NASDAQ:STRO - TradingView
Price to sales forward of Sutro Biopharma, Inc. – NASDAQ:STRO - TradingView
Price to book forward of Sutro Biopharma, Inc. – NASDAQ:STRO - TradingView
Sutro Biopharma (STRO) price target increased by 13.85% to 37.74 - MSN
Sutro Biopharma, Inc.(NasdaqGM:STRO) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 2500 Growth Benchmark - marketscreener.com
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 2000 Index - marketscreener.com
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 2000 Value Benchmark - marketscreener.com
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 2000 Growth Benchmark - marketscreener.com
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 3000E Index - marketscreener.com
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 3000E Value Benchmark - marketscreener.com
Sutro Biopharma, Inc.(NasdaqGM: STRO) added to Russell 2500 Index - marketscreener.com
Sutro Biopharma, Inc. Actuals & Estimates (LSX:A41VMF) - TradingView
Sutro Biopharma, Inc. Actuals & Estimates (NASDAQ:STRO) - TradingView
Sutro Biopharma, Inc. Actuals & Estimates (FWB:S090) - TradingView
STRO Forecast — Price Target — Prediction for 2027 - TradingView
S090 Forecast — Price Target — Prediction for 2027 - TradingView
Sutro Biopharma, Inc. Actuals & Estimates (GETTEX:S090) - TradingView
Sutro Biopharma Inc (STRO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Sutro Biopharma CSO Hans-Peter Gerber to join 2026 BIO International Convention panel - Traders Union
Barclays Maintains Sutro Biopharma(STRO.US) With Buy Rating, Maintains Target Price $56 - Moomoo
Sutro Biopharma Inc (STRO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Sutro Biopharma Inc (STRO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Sutro Biopharma Inc (STRO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Sutro Biopharma Inc (STRO) Institutional Confidence - TradingKey
Sutro Biopharma Inc (STRO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Sutro Biopharma Inc (STRO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sutro Biopharma Inc (STRO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Sutro Biopharma Inc (STRO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
This drug 'gave our daughter another chance' — now a nonprofit's deal hopes to secure its use for years to come - The Business Journals
Sutro Biopharma (STRO) Surges Over 9% as Buyers Test Key Resistance at $30.54Elliott Wave Entry - newsline.com
Sutro Biopharma Price Target Announced at $50.00/Share by Truist Securities - Moomoo
Truist Financial Initiates Sutro Biopharma(STRO.US) With Buy Rating, Announces Target Price $50 - Moomoo
Sutro Biopharma (STRO) Proxy filing Summary - Quartr
Sutro Biopharma (STRO) director receives 10,000 stock options at $26.09 - Stock Titan
Sutro Biopharma (STRO) director granted 10,000 stock options at $26.09 - Stock Titan
Sutro Biopharma (STRO) director awarded 10,000 stock options at $26.09 strike - Stock Titan
Sutro Biopharma (STRO) director receives 10,000 options vesting into 2027 - Stock Titan
Sutro Biopharma (STRO) director receives 10,000-share stock option grant - Stock Titan
[Form 4] SUTRO BIOPHARMA, INC. Insider Trading Activity - Stock Titan
Sutro Biopharma (STRO) director receives grant of 10,000 stock options - Stock Titan
Director at Sutro Biopharma (STRO) receives 10,000 stock options as equity grant - Stock Titan
Sutro Biopharma (NASDAQ: STRO) reports 2026 annual meeting results - Stock Titan
Sutro Biopharma Surges 5.52% – Testing Key Resistance at $30.11 After Strong SessionAdvance Decline Volume - newsline.com
Sutro Biopharma (STRO) CFO exercises 2,500 RSUs and increases direct holdings - Stock Titan
STRO Q1 2026 Earnings: Narrower Loss Beats Estimates as Sutro Biopharma Advances PipelineTech Earnings Analysis - The Legal Advocate
Barclays Initiates a Buy Rating on Sutro Biopharma (STRO) - The Globe and Mail
STRO Initiated Coverage by Barclays -- Rating Set to Overweight - GuruFocus
Barclays Initiates Sutro Biopharma at Overweight With $56 Price Target - marketscreener.com
Sutro Biopharma Inc Azioni (STRO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Sutro Biopharma Inc Azioni (STRO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 04 '26 |
Option Exercise |
0.00 |
675 |
0 |
10,025 |
| Chung Jane | Chief Executive Officer |
Mar 04 '26 |
Option Exercise |
0.00 |
788 |
0 |
21,567 |
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 02 '26 |
Option Exercise |
0.00 |
2,356 |
0 |
10,320 |
| Pauling David | Chief Admin. Ofcr. & GC |
Mar 01 '26 |
Option Exercise |
0.00 |
1,342 |
0 |
8,515 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 02 '26 |
Option Exercise |
0.00 |
2,843 |
0 |
10,688 |
| Gerber Hans-Peter | CHIEF SCIENTIFIC OFFICER |
Mar 01 '26 |
Option Exercise |
0.00 |
1,125 |
0 |
8,308 |
| Chung Jane | Chief Executive Officer |
Mar 02 '26 |
Option Exercise |
0.00 |
7,750 |
0 |
23,558 |
| Chung Jane | Chief Executive Officer |
Mar 01 '26 |
Option Exercise |
0.00 |
3,188 |
0 |
17,079 |
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):